Deep Dive - Updating Opioid Treatment and Documentation Methods | Treatment Options - MAT and your patients

Evaluation and Claim Credit

1. Once you begin the video, you must watch it in its entirety to claim credit. Fast-forwarding has been disabled. You may pause the video briefly if needed. Do not close the browser window as doing so will require you to start over.
2. Once you have reached the end of the video, a button to continue will appear that will take to evaluation and start the process for receiving a certificate.
3. Failure to complete the process will result in the credit not being awarded to you.
4. Should you need to restart the process, or download a copy of a certificate at a later time, please see the instructions for accessing the online portal here: Evaluation and Claim Credit

For questions concerning the online evaluation or your certificate, please contact our office at (775) 784-4791 or email us at cme@med.unr.edu.

Accreditation Designation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Nevada Rural Health Partners (NRHP). The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.

The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education Credit

The University of Nevada, Reno School of Medicine approves this program for 1.00 hour of nursing continuing education credit. Nevada State Board of Nursing provider number 120894-1.

As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.

The following presenters have disclosed the following relationship with a commercial interest.

Denis Patterson (presenter):

• Grant/Research Support: Abbott, Biotronik, Nuvectra, Nevro, Flowonix, Vertiflex
• Consultant: Allergan, Amgen, Abbott, CornerLoc, Flownix, Saluda
• Speakers' Bureau or Honoraria: Allergan, Amgen, Abbott, CornerLoc, Flownix

All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that they do not have financial relationships with ineligible companies related to the content of this activity..

• Centers for Disease Control and Prevention, National Center for Health Statistics. (2020). Multiple cause of death 1999-2017 [Data set]. CDC WONDER Online Database. Retrieved from CDC WONDER Multiple Cause of Death Data
• Volpe, D. A., Tobin, G. A. M., Mellon, R. D., et al. (2011). Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs. Regulatory Toxicology and Pharmacology, 59(3), 385-390.
• U.S. Drug Enforcement Administration. (n.d.). Acetylfentanyl: Information sheet on the chemical properties and risks.
• Drug Enforcement Administration. (n.d.). Five quick facts about Carfentanil. Retrieved from DEA Just Think Twice: Carfentanil Overview
• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
• Nestler, E. J. (2005). Is there a common molecular pathway for addiction? Nature Neuroscience, 8(11), 1445-1449.
• National Institute on Drug Abuse. (2020, July). Drugs, brains, and behavior: The science of addiction. Retrieved from NIDA Science of Addiction Resource
• Hedegaard, H., Miniño, A. M., & Warner, M. (2020). Drug overdose deaths in the United States, 1999-2018 (NCHS Data Brief No. 356). CDC, National Center for Health Statistics. Retrieved from CDC NCHS Data Brief on Overdose Deaths
• O’Donnell, J., Gladden, R. M., Goldberger, B. A., Mattson, C. L., & Kariisa, M. (2020). Notes from the field: Opioid-involved overdose deaths with fentanyl or fentanyl analogs detected—United States, July 2016-December 2018. Morbidity and Mortality Weekly Report, 69(9), 271-273. Retrieved from CDC MMWR Report on Fentanyl-related Deaths
• Meier, B. (2003). Pain Killer: A "wonder" drug's trail of addiction and death. Emmaus, PA: Rodale Press.
• Porter, J., & Jick, H. (1980). Addiction rare in patients treated with narcotics. New England Journal of Medicine, 302(2), 123.
• Perry, S., & Heidrich, G. (1982). Management of pain during debridement: A survey of US burn units. Pain, 13(3), 267-280.
• Institute of Medicine. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education, and research. Retrieved from National Academies Report on Pain Management
• Rich, S. J. (2009). Advances in pain management for pharmacists. Advanced Studies in Pharmacy, 6(4), 115-119.
• Manchikanti, L., et al. (2009). American pain physician guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2. Pain Physician, 12, 699-802. Retrieved from Pain Physician Journal Archive
• Wang, Y., et al. (2008). Obesity and chronic pain prevalence in the U.S. Obesity, 16(10), 2323-2330.
• National Institute on Drug Abuse. (2021). NIDAMED: Clinical resources for health professionals. Retrieved from NIDA Medical Resources Portal
• Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA, 315(15), 1624-1645.
• Holmes, C. P., et al. (2006). An opioid screening instrument: Long-term evaluation of the utility of the pain medication questionnaire. Pain Practice, 6(2), 74-88.
• PainEDU. (n.d.). Pain education for clinicians. Retrieved from PainEDU Educational Resource